Skip to main content

Table 2 Investigational parameters at baseline, after 12 and 24 weeks of treatment in the observational groups

From: Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study

  Baseline 12 weeks 24 weeks
  Glimepiride Vildagliptin Glimepiride Vildagliptin Glimepiride Vildagliptin
HbA1c (%) 7.28 ± 0.59 7.41 ± 0.74 6.70 ± 0.50 * 6.95 ± 0.82 * 6.57 ± 0.45 * 6.74 ± 0.75 *
Fasting BG (mmol/L) 8.2 ± 1.9 8.4 ± 1.5 7.0 ± 1.2 * 7.6 ± 1.9 7.0 ± 1.2 * 7.4 ± 1.4 *
Adiponectin (μg/mL) 5.6 ± 3.1 5.0 ± 3.5 5.4 ± 2.8 5.5 ± 4.1 5.7 ± 2.7 5.7 ± 4.1 *
Body weight (kg) 93.7 ± 19.6 99.3 ± 14.9 94.4 ± 18.9 98.7 ± 15.0 95.5 ± 19.0 97.6 ± 14.3 *
RBF (AU) 74.2 ± 5.3 75.1 ± 5.8 74.7 ± 6.9 75.3 ± 5.8 76.1 ± 7.6 77.9 ± 5.9 *
WLR (AU) 0.47 ± 0.08 0.46 ± 0.06 0.45 ± 0.09 0.43 ± 0.07 0.43 ± 0.08 0.40 ± 0.06 *
EI AUC0.3–60 (AU*min) 2536 ± 228 2568 ± 196 2505 ± 256 2570 ± 170 2682 ± 240 * 2623 ± 210 *
  1. BG =blood glucose; RBF =Retinal blood flow; WLR = arteriolar wall to lumen ratio; EI AUC0.3–60 = area under curve for the elongation index in the shear stress range of 0.3-60 Pa; mean ± SD; * = p < 0.05 vs. baseline.